Home > Cardiology > ACC 2022 > Myocardial Infarction > Sodium thiosulfate ineffective at cardiac protection

Sodium thiosulfate ineffective at cardiac protection

Presented By
Dr Marie-Sophie de Koning, University Medical Center Groningen, the Netherlands
ACC 2022
Phase 2, GIPS-IV
The first-in-human clinical trial to test sodium thiosulfate to reduce infarct size after heart attacks in humans did not show benefits for any of the primary or secondary endpoints in the GIPS-IV trial at 4 months, despite promising preclinical evidence. The multicentre, double-blind, randomised-controlled, phase 2 GIPS-IV trial (NCT02899364), presented by the study’s lead author, Dr Marie-Sophie de Koning (University Medical Center Groningen, the Netherlands), explored the feasibility of sodium thiosulfate for the preservation of cardiac function after ST-elevation myocardial infarction (STEMI) [1]. The rationale behind this trial was that the strong antioxidant sodium thiosulfate produces hydrogen sulfide, which in turn has been shown to reduce ischaemia-reperfusion injury after a heart attack in an abundance of preclinical evidence. Sodium thiosulfate b...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on